Cutler Group’s Kazia Therapeutics KZIA Stock Holding History

Cutler Group’s Portfolio KZIA Stock Details KZIA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-8	Closed	-$3K	–	5987
2020 Q4	$3K	Buy	+8	New	+$3.19K	﹤0.01%	3970

Other funds holding KZIA

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return

Truist Financial Charlotte, North Carolina $74.2B AUM 21.09% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

SFI

Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return

Transform Wealth Greenwood Village, Colorado $1.65B AUM 19.1% 1-Year Est. Return

TCWM

Total Clarity Wealth Management St. Charles, Illinois $515M AUM 27.37% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

Cutler Group's KZIA Position: Q1 2021 in Review

Cutler Group sold out of Kazia Therapeutics (KZIA) in Q1 2021, closing a stake of 8 shares — an estimated $3K sold.

Cutler Group first reported a position in KZIA in Q4 2020 and held it in 1 quarter. The position peaked at $3K in Q4 2020. 12 funds tracked by Wall St. Rank hold KZIA as of Q1 2021.

Cutler Group reported no remaining Kazia Therapeutics position as of Q1 2021 after selling out during the quarter.
Cutler Group sold 8 Kazia Therapeutics shares in Q1 2021, an estimated $3K.
Cutler Group first reported a position in Kazia Therapeutics in Q4 2020 and held it in 1 quarter.
Cutler Group's Kazia Therapeutics position peaked at $3K in Q4 2020.
12 funds tracked by Wall St. Rank held Kazia Therapeutics as of Q1 2021.

Based on Cutler Group's 13F filing for Q1 2021, filed 26 Apr 2021.